Rosalind Advisors Increases Myomo Stake

Rosalind Advisors has increased its stake in Myomo Inc by acquiring 4.66% of the company's shares, bringing its total holdings to 7.37% of Myomo's portfolio. Myomo is a wearable medical robotics company that has experienced financial challenges, including a -84.95% year-to-date price change and a GF-Score of 57/100. The investment carries inherent risks, but Rosalind Advisors may be banking on Myomo's innovative product offerings.

Rosalind Advisors, Inc. has significantly increased its stake in Myomo Inc by acquiring an additional 4,655,385 shares of the wearable medical robotics company. This move, executed at a trade price of $2.16 per share, represents a strategic addition to Rosalind Advisors' portfolio. The acquisition resulted in a 4.66% increase in Rosalind Advisors' holdings of Myomo Inc, bringing the total to 7,359,046 shares, which now represents 7.37% of the firm's portfolio and 9.90% of Myomo Inc's total shares [1].

Myomo Inc specializes in developing myoelectric orthotics for individuals with neuromuscular disorders. Despite its innovative products, the company has faced significant financial challenges. The company's year-to-date price change is a substantial -84.95%, and its GF-Score is 57/100, indicating poor future performance potential. Key financial metrics reveal a Balance Sheet Rank of 5/10, a Profitability Rank of 1/10, and a Growth Rank of 7/10. The company's Cash to Debt ratio is 1.25, with a Return on Equity (ROE) of -56.17% and a Return on Assets (ROA) of -30.21% [1].

Recent financial results from Myomo Inc have been mixed. In the second quarter of 2025, the company reported second-quarter revenue of $9.7 million, up 28% year-over-year, beating internal projections. However, the company's 2025 revenue guidance was slashed to $40-42 million from the previous range of $50-53 million, citing lead quality issues and lower conversion rates. Operating losses widened to $4.6 million from $1.1 million in the prior year quarter. Net loss per share increased to $0.11 from $0.03, while adjusted EBITDA loss expanded to $4.0 million from $1.2 million year-over-year [2].

Despite these challenges, Rosalind Advisors' investment in Myomo Inc may be seen as a long-term play, potentially banking on the company's innovative product offerings. However, given Myomo Inc's current financial standing and market performance, this investment carries inherent risks. Investors should consider the firm's strategy in the context of Myomo Inc's Piotroski F-Score of 4 and Altman Z score of -2.17, which suggest caution [1].

References:
[1] https://www.gurufocus.com/news/3065576/rosalind-advisors-inc-increases-stake-in-myomo-inc
[2] https://www.benzinga.com/markets/equities/25/08/47052556/myomo-shares-plunge-over-42-pre-market-despite-q2-revenue-beat-amid-weak-outlook-rising-losses